Not Out Of The Dark Yet: UK’s NICE Turns Down Clinuvel’s Phototoxicity Drug Scenesse
Executive Summary
NICE has issued a preliminary assessment in which it recommends against public funding in England for Clinuvel’s novel drug Scenesse for the ultra-rare condition, erythropoietic protoporphyria (EPP). The company says it intends to pursue reimbursement in the coming months.
You may also be interested in...
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.
Will NICE Change Its Mind On Scenesse After UK Public Hearing?
This month should see the outcome of a public hearing held to discuss the decision by the UK's health technology assessment body, NICE, not to recommend funding for Clinuvel’s Scenesse, a novel treatment for the ultra-rare condition, erythropoietic protoporphyria.
Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings
The latest drug development news and highlights from our US FDA Performance Tracker.